Experience of incritinomimetic exenatide (Byetta) use in the treatment of patients with type 2 diabetes mellitus with obesity


如何引用文章

全文:

详细

Diabetes mellitus type 2 (CD2) is often accompanied by cardiovascular disease (CVD), having identical mechanisms of development. Risk factors for rapid development and progression of CVD include hypertension, noncompensated DM, and dyslipidemia. Therefore it is of critical importance that the modern drugs used in diabetes management not only had a high therapeutic activity in relation to glycemia, but also had effect on blood pressure (BP) and dyslipidemia. These drugs include incretinomimetic exenatide (Byetta), which has pancreatic and extrapancreatic mechanisms of action. Exenatide has glucose-dependent insulinotropic effect on beta-cells of pancreas, improving two-phase insulin secretion. It also reduces the secretion of glucagon by the alpha-cells of the pancreas, resulting in decreased production of glucose by the liver, especially in the postprandial period. The extrapancreatic effects of the drug include: delayed gastric emptying, appetite suppression, decrease of blood pressure level, increase of high-density lipoprotein level and decrease of cholesterol, triglycerides, and low density lipoprotein levels, and decrease in body weight. Exenatide administration open new possibilities in the treatment of type 2 diabetes and allow avoiding the development of CVD.

参考

  1. Buse JB, Ginsberg HN, Bakris GL, et al. Primary rtevention of cardiovascular diseases in people with diabetes mellitus. Diabetes Care 2007;30:162-72.
  2. Buse JB, Henry RR, Han J, et al. Effects of exenatide ( exendin-4) on glycemic control over 30 weeks in sulfonylurea - treated patients with type 2 diabetes Diabetes Care 2004;27(11):2628-35.
  3. Buteau J, Roduit R, Susini S, et al. Glucagon-like peptide - 1 promotes DNA synthesis, activates phosphatidynalinositol , 3-kinase and increases transcription factor pancreatic and duodenalhomebox gene 1(PDX-1) DNA binding activity in beta (INS-1)-cells. Diabetologia 1999;42:856-64.
  4. DeFronzo RA, Ratner RE, Han J, et al. Effects of exenatide ( exendin-4) on glycemic control and weight over 30 weeks in metformin - treated patients with type 2 diabetes Diabetes Care 2005;28(5):1092-100.
  5. Deacon CF, Nauck MA, Toft-Nielsen M, et al. Both subcutaneously and intravenously administred glucagon-like peptide I are rapidly degraded from the NH2 - terminus in type II diabetic patients and healthy subjects. Diabetes 1995;44:1126-31.
  6. Edwards CMB, Stanley SA, Davis R, et al. Exendin-4 reduses fasting and postprandial glucose decreases energy intake in healthy volunteers. Am J Physiol Endocrinol Metab 2001;281(1):E155-61.2.
  7. Elrick H, Stimmler L, Hlad CJ, et al. Plasma insulin responses to oral and intravenous glucose administration. J Clin Endocrinol Metab 1964;24:1076-82.
  8. Egan JM, Clocquet AR, Elabi D. The insulinotropic effect of acute exendin-4 administered to humans: comparison of nondiabetic state to type 2 diabetes. J Clin Endocrinol Metab 2002;87(3):1282-90.
  9. Fehmann HC, Habener JF. Insulinotropic hormone glucagon-like peptide-1 (7-37) stimulation of proinsulin biosynthesis in insulinoma beta TC-1 cells. Endocrinology 1992;130:156-66.
  10. Fehse FC, Trautmann ME, Holst JJ, et al. Exenatide augments first-and second -phase insulin secretion in response to intravenous glucose in subjects with type 2 diabetes. J Clin Endocrinol Metab 2005;90:5991-97.
  11. Ноlst JJ, Gromada J. Role of incretin hormones in the regulation of insulin secretion in diabetic and nondiabetic humans. Am J Physiol Endocrinol Metab 2004;287(2):E199-206.
  12. Keating GM. Exenatide. Drugs 2005;65(12):1681-82.
  13. Kendall DM, Kim D, Poon T, et al. Improvements in cardiovascular risk factors accompanied sustained effects on glucemia and weight reduction in patients with type 2 diabetes treated with exenatide for 82 wk [abstract no.16-OR]. Diabetes 2005;54(1):A4-5.
  14. Kendall DM, Riddle MC, Rosenstock J, et al. Effects of exenatide (exendin-4) on glucemic control over 30 weeks in patients with type 2 diabetes treated with metformi and a sulfonyleria. Diabetes Care 2005;28(5):1083-91.
  15. http://www.pharmateca.ru/cgi-bin/statyi.pl?sid=2213&mid=1085056570&magid=166

补充文件

附件文件
动作
1. JATS XML
下载
##common.cookie##